Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Ura

Showing results (71-80 of 85) with videos related to

Pageof 9
Sort By:
American Journal of Hypertension|April 1, 1995
Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensivesO Iimura, K Shimamoto, K Matsuda, et al.
Advances in Experimental Medicine and Biology|January 1, 1989
Localization of neutral endopeptidase in the kidney determined by the stop-flow methodT Sakakibara, N Ura, K Shimamoto, et al.
Advances in Experimental Medicine and Biology|January 1, 1989
A sensitive method for differential determination of kininase I, II and neutral endopeptidase (NEP) in human urineH Ogata, N Ura, K Shimamoto, et al.
Endocrinologia Japonica|December 1, 1983
A case of 17 alpha-hydroxylase deficiency with special reference to the renal kallikrein-kinin systemT Mita, K Shimamoto, N Ura, et al.
Advances in Experimental Medicine and Biology|January 1, 1986
The role of renal kallikrein-kinin system and prostaglandins in diuresis and natriuresis following saline infusion in normotensives and essential hypertensivesT Nishimiya, K Shimamoto, S Tanaka, et al.
Hypertension (Dallas, Tex. : 1979)|October 1, 1989
Mechanisms of suppression of renal kallikrein activity in low renin essential hypertension and renoparenchymal hypertensionK Shimamoto, A Masuda, T Ando, et al.
Advances in Experimental Medicine and Biology|January 1, 1986
The method of urinary total kallikrein and prekallikrein measurement, and their urinary excretions in the patients with essential hypertensionS Tanaka, K Shimamoto, N Ura, et al.
Nephron|January 25, 2000
Hypoparathyroidism potentiates cardiovascular complications through disturbed calcium metabolism: possible risk of vitamin D(3) analog administration in dialysis patients with end-stage renal diseaseK Tsuchihashi, H Takizawa, T Torii, et al.
Clinical and Experimental Hypertension. Part A, Theory and Practice|January 1, 1987
Role of renin-angiotensin and kallikrein-kinin systems on the mechanism of the hypotensive effects of converting enzyme inhibitor, alaceprilS Tanaka, K Shimamoto, T Ando, et al.
Heart (British Cardiac Society)|October 20, 1999
Mobile intracardiac calcinosis: a new risk of thromboembolism in patients with haemodialysed end stage renal diseaseK Tsuchihashi, A Nozawa, S Marusaki, et al.
Pageof 9

Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
American Journal of Hypertension|April 1, 1995
Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensivesO Iimura, K Shimamoto, K Matsuda, et al.
Advances in Experimental Medicine and Biology|January 1, 1989
Localization of neutral endopeptidase in the kidney determined by the stop-flow methodT Sakakibara, N Ura, K Shimamoto, et al.
Advances in Experimental Medicine and Biology|January 1, 1989
A sensitive method for differential determination of kininase I, II and neutral endopeptidase (NEP) in human urineH Ogata, N Ura, K Shimamoto, et al.
Endocrinologia Japonica|December 1, 1983
A case of 17 alpha-hydroxylase deficiency with special reference to the renal kallikrein-kinin systemT Mita, K Shimamoto, N Ura, et al.
Advances in Experimental Medicine and Biology|January 1, 1986
The role of renal kallikrein-kinin system and prostaglandins in diuresis and natriuresis following saline infusion in normotensives and essential hypertensivesT Nishimiya, K Shimamoto, S Tanaka, et al.
Hypertension (Dallas, Tex. : 1979)|October 1, 1989
Mechanisms of suppression of renal kallikrein activity in low renin essential hypertension and renoparenchymal hypertensionK Shimamoto, A Masuda, T Ando, et al.
Advances in Experimental Medicine and Biology|January 1, 1986
The method of urinary total kallikrein and prekallikrein measurement, and their urinary excretions in the patients with essential hypertensionS Tanaka, K Shimamoto, N Ura, et al.
Nephron|January 25, 2000
Hypoparathyroidism potentiates cardiovascular complications through disturbed calcium metabolism: possible risk of vitamin D(3) analog administration in dialysis patients with end-stage renal diseaseK Tsuchihashi, H Takizawa, T Torii, et al.
Clinical and Experimental Hypertension. Part A, Theory and Practice|January 1, 1987
Role of renin-angiotensin and kallikrein-kinin systems on the mechanism of the hypotensive effects of converting enzyme inhibitor, alaceprilS Tanaka, K Shimamoto, T Ando, et al.
Heart (British Cardiac Society)|October 20, 1999
Mobile intracardiac calcinosis: a new risk of thromboembolism in patients with haemodialysed end stage renal diseaseK Tsuchihashi, A Nozawa, S Marusaki, et al.
Pageof 9